Economic Evaluation of Multiple-Pharmacogenes Testing for the Prevention of Adverse Drug Reactions in People Living with HIV

Saowalak Turongkaravee1,2, Naiyana Praditsitthikorn2, Thndon Ngamprasertchais3, Jiraphun Jittikoon4, Surakameth Mahasirimongkol5, Chonaphat Sukasem6–9, Wanvisa Udomsinprasert4, Olivia Wu10, Usa Chaikledkaew1,11,12

1Social, Economic and Administrative Pharmacy (SEAP) Graduate Program, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand; 2Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand; 3Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; 4Department of Biochemistry, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand; 5Department of Medical Sciences, Medical Genetics Center, Medical Life Sciences Institute, Ministry of Public Health, Nonthaburi, Thailand; 6Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; 7Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), Ramathibodi Hospital, Bangkok, Thailand; 8Pharmacogenomics and Precision Medicine, The Preventive Genomics & Family Check-Up Services Center, Bumrungrad International Hospital, Bangkok, Thailand; 9MRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, L69 3GL, UK; 10Health Economics and Health Technology Assessment (HEHTA), Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK; 11Social and Administrative Pharmacy Division, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand; 12Mahidol University Health Technology Assessment (MUHTA) Graduate Program, Mahidol University, Bangkok, Thailand

Correspondence: Usa Chaikledkaew, Social and Administrative Pharmacy Division, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, 447 Sri-Ayudhaya Road, Rajathevi, Bangkok, 10400, Thailand, Tel +66-644-8679 ext 5317, Fax +66-644-8694, Email usa.chi@mahidol.ac.th

Purpose: Pharmacogenetics (PGx) testing is one of the methods for determining whether individuals are at risk of adverse drug reactions (ADRs). It has been reported that multiple-PGx testing, a sequencing technology, has a higher predictive value than single-PGx testing. Therefore, this study aimed to determine the most cost-effective PGx testing strategies for preventing drug-induced serious ADRs in human immunodeficiency virus (HIV)-infected patients.

Patients and Methods: Potential strategies, including 1) single-PGx testing (ie, HLA-B*57:01 testing before prescribing abacavir, HLA-B*13:01 testing before prescribing co-trimoxazole and dapsone, and NAT2 testing before prescribing isoniazid) and 2) multiple-PGx testing as a combination of four single-gene PGx tests in one panel, were all compared to no PGx testing (current practice). To evaluate total cost in Thai baht (THB) and quality-adjusted life years (QALYs) for each strategy-based approach to a societal perspective, a hybrid decision tree and Markov model was constructed. Incremental cost-effectiveness ratios (ICERs) were estimated. Uncertainty, threshold, and scenario analyses were all performed.

Results: Before prescribing HIV therapy, providing single or multiple-PGx testing might save roughly 68 serious ADRs per year, and the number needed to screen (NNS) to avoid one serious ADR was 40. Consequently, approximately 35% and 40% of the cost of ADR treatment could be avoided by the implementation of single- and multiple-PGx testing, respectively. Compared with no PGx testing strategy, the ICERs were 146,319 THB/QALY gained for single-PGx testing and 152,014 THB/QALY gained for multiple-PGx testing. Moreover, the probability of multiple-PGx testing being cost-effective was 45% at the Thai willingness to pay threshold of 160,000 THB per QALY. Threshold analyses showed that multiple-PGx testing remained cost-effective under the range of cost, sensitivity at 0.95–1.00 and specificity at 0.98–1.00.

Conclusion: Single and multiple-PGx testing might be cost-effective options for reducing the incidence of drug-induced serious ADRs in people living with HIV.

Keywords: pharmacogenetic, adverse drug reactions, HIV, cost-utility analysis, economic evaluation

Introduction

Human Immunodeficiency Virus (HIV) infection/acquired immunodeficiency syndrome (AIDS) was the fifth leading cause of death and poses a significant disease burden among Thai people. The incidence per 1000 population was 0.08
for all ages, with an estimated 5400 new HIV infections per year. Since 2014, HIV/AIDS guidelines have been developed in collaboration with the Department of Disease Control, Ministry of Public Health and the Thai AIDS Society, with a significant change that people living with HIV can now access antiretroviral treatment (ART) for free and immediately upon diagnosis. This was consistent with the recommendation of the United State (US) Department of Health and Human Services (DHHS) panel denoting that ART should be provided to all HIV-positive individuals. Until now, people living with HIV have been treated for free through the support of all Thai health insurance schemes. However, drug-related adverse drug reactions (ADRs) frequently lead to non-compliance, virological failure, substantial treatment costs, and poor quality of life, given that people living with HIV are more susceptible to ADRs than the general population. It has been well recognized that HIV therapy consisting of ART and opportunistic infections can cause serious ADRs including abacavir-induced hypersensitivity reaction (HSR), co-trimoxazole-induced Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN), drug-induced rash with eosinophilia and systemic symptoms (DRESS), and isoniazid-induced hepatotoxicity.

Nowadays, genetic factors are widely known to influence the efficacy and toxicity of pharmacological treatment. Supporting this, numerous studies demonstrated significant associations between genetic polymorphisms and drug induced-serious ADRs in not only ART regimens like abacavir, but also opportunistic infection therapy including co-trimoxazole, dapsone, and isoniazid. In addition to these previous findings, a meta-analysis uncovered that patients who carried HLA-B*57:01 were more likely than non-carriers to develop abacavir-induced HSR. Based on this premise, the United States Food and Drug Administration (USFDA) recommended that HLA-B*57:01 genetic screening should be standard practice for all patients receiving abacavir treatment. Apart from the significant influence of HLA-B*57:01 associated with abacavir-induced HSR, further meta-analysis and phenotype stratification study revealed a substantial association between HLA-B*13:01 and co-trimoxazole–induced DRESS. In Thai people, HLAB*13:01 allele was observed to be significantly associated with co-trimoxazole-induced SJS/TEN when compared to co-trimoxazole-tolerant controls. In Thai non-leprosy patients, HLAB*13:01 was also significantly associated with dapsone-induced severe cutaneous adverse reactions (SCARs). Aside from effects of HLA genetic polymorphisms on drug induced-serious ADRs, several meta-analyses demonstrated that tuberculosis (TB) patients with slow/intermediate N-acetyltransferase 2 (NAT2) acetylators had a higher risk of isoniazid-induced liver injury than those with rapid acetylators. The aforementioned findings lend support to the notion that identifying genetic polymorphisms of pharmacogenes may pave the way to personalized medicine in the context of ADRs.

In support of the above assumption, previously published findings indicated that performing pharmacogenetic (PGx) testing before prescribing medication might help reduce the risk of developing serious ADRs. In Thailand, only HLA-B*15:02 testing is required before prescription carbamazepine for epilepsy patients, and HLA B*57:01 testing is needed before prescription allopurinol for gout patients under the Universal Health Coverage (UHC) scheme, which covers around 80% of Thai population. Despite this, there are over 70 PGx tests accessible at medical school laboratories and 14 regional lab centers operated by the Department of Medical Sciences, Ministry of Public Health. To date, technological advancements like a sequencing method have made it possible to test numerous genes in a short period of time, which may have a higher predictive value than single-gene testing. Therefore, multiple-PGx testing will be necessary to explore a variety of potential treatment pathways. However, the cost of multiple-PGx testing is still expensive, and no cost-effectiveness information has been provided to assist policymakers in making rationale resource allocation decision. Accordingly, the purpose of this study was to evaluate the cost-utility of single-PGx testing of HLA-B*57:01 before prescribing abacavir to prevent HSR, HLA-B*13:01 before prescribing co-trimoxazole to prevent DRESS, HLA-B*13:01 before prescribing dapsone to prevent SCAR, and NAT2 before prescribing isoniazid to prevent hepatotoxicity in people living with HIV as well as multiple-PGx testing, which is a combination of four aforementioned single-PGx tests compared to no PGx testing as a current practice.

Materials and Methods
Study Design
A hybrid decision tree and Markov model was developed to evaluate a cost-utility of a single- and multiple-PGx testing strategy before starting drug therapy in people living with HIV compared with those prescribed drug therapy without
PGx testing. The incremental cost-effectiveness ratio (ICER) was calculated in terms of cost per quality-adjusted life-year (QALY). The assessment was made from a societal perspective.

**Target Population**
The model simulated cohorts of newly diagnosed HIV patients who received ART and treatment for opportunistic infections such as Pneumocystis jiroveci Pneumonia (PCP) and TB.

**Interventions and Comparator**
Studied interventions included four single-PGx tests and multiple-PGx testing that merged those single-PGx tests, which were all compared to no PGx testing as a current practice. The following details were provided.

**Single-PGx Testing**
Single PGx testing included 1) *HLA-B*^57:01^ before starting abacavir to prevent HSR, 2) *HLA-B*^13:01^ before prescribing co-trimoxazole to prevent DRESS, 3) *HLA-B*^13:01^ before prescribing dapsone to prevent SCAR, and 4) *NAT2* before prescribing isoniazid to prevent hepatotoxicity. Prior to initiating any medication regimen, newly diagnosed HIV patients were all tested sequentially. Patients who get a positive test result would be prescribed the alternative regimen, whereas those with a negative test result would continue the initial regimen.

**Multiple-PGx Testing**
Multiple-PGx testing included four single-PGx tests in a single panel. Patients who test positive for each test would be prescribed the alternative regimen, whereas patients who test negative would remain on the initial regimen. All newly diagnosed HIV patients were tested just once before starting drug therapy.

**No PGx Testing**
Patients newly diagnosed with HIV infection were treated with the first-line ART regimen and opportunistic infection therapy without undergoing PGx testing. Based on the Thailand’s National Guidelines on HIV/AIDS Diagnosis, Treatment, and Prevention 2020/2021, the first-line NRTI backbone regimen consists of a combination of tenofovir/emtricitabine (TDF 300 milligram (mg)/FTC 200 mg or TAF 25 mg/FTC 200 mg) plus dolutegravir (DTG) 50 mg, tenofovir-containing regimens. If patients developed serious ADRs due to the first-line treatment, abacavir/lamivudine (ABC 600 mg/3TC 300 mg) with DTG 50 mg, abacavir-containing regimens would be recommended as the second-line ART regimen. If a patient taking abacavir developed a suspected HSR, zidovudine/lamivudine (AZT 600 mg/3TC 300 mg) with DTG 50 mg, zidovudine-containing regimen recommended as the third-line ART regimen. As a result, the ART regimen was provided life-long treatment.

Based on Thailand’s National Guidelines on HIV/AIDS Diagnosis and international guidelines, co-trimoxazole or trimethoprim/sulfamethoxazole (TMP/SMX), 80 mg TMP plus 400 mg SMX (1–2 tablets) daily or 160 mg TMP plus 800 mg SMX three times per week was recommended as the drug of choice for primary prophylaxis of PCP in people living with HIV. Whereas 15 to 20 mg/kg (based on the TMP component) given in 3 or 4 equally divided doses every 6 to 8 hours for up to 14 days was recommended for the treatment of PCP. In patients who had serious ADRs to co-trimoxazole or other sulfa-drugs, either dapsone 100 mg daily or intravenous pentamidine 300 mg monthly could be used as an alternative for PCP prophylaxis. Moreover, clindamycin 600 mg plus primaquine 30 mg for 21 days could be used as the treatment of PCP.

Regarding TB infection, the Thailand National Guidelines on TB/HIV and the World Health Organization (WHO) recommended the first-line treatment regimen for TB comprising a combination of isoniazid 5–8 mg/kg (or 300 mg), rifampicin 10 mg/kg (or 450–600 mg), pyrazinamide 25 mg/kg (or 1000–2000 mg), and ethambutol 25 mg/kg (or 800–1200 mg) as an initial treatment regimen for the first two months followed by isoniazid and rifampicin for four months. In patients who developed hepatotoxicity, half the standard isoniazid dosage for nine months was recommended to prevent hepatotoxicity from isoniazid.
Model Structure
A combination of a hybrid of decision tree and Markov models was constructed based on the clinical practice in accordance with the Thailand’s National Guidelines on HIV/AIDS Diagnosis, Treatment, and Prevention 2020/2021.6 The model was used to determine lifetime costs and health outcomes between people living with HIV receiving either single or multiple PGx testing before starting drug therapy compared with those who did not get PGx testing. From this, the model started with the same adult cohort, individuals newly diagnosed HIV and aged more than 30 years old. The lifetime time horizon was employed with a one-year cycle length. Costs and outcomes were discounted at a rate of 3% per annum based on Thailand’s and the World Health Organization’s guidelines for health technology assessment.28,29

Figure 1A depicts the decision tree model displaying three treatment options for newly diagnosed HIV-infected patients, namely no PGx testing, single-PGx testing, and multiple-PGx testing, which combined four single-PGx tests in a single panel. If the patients had a positive test result of each testing, they would receive the alternative drug regimen. The first-line ART treatment starts with tenofovir-containing regimens; if they develop serious ADRs such as nephrotoxicity or if tenofovir is contraindicated, they are switched to ABC-containing regimens. Afterwards, when the condition progressed, treatment for opportunistic infection was provided.

Five possible events were identified in patients with CD4 counts <200 cells per mm$^3$: 1) asymptomatic HIV infection: patients would initially receive ART, co-trimoxazole prophylaxis and INH for latent TB; 2) symptomatic PCP infection: patients would start with ART, co-trimoxazole treatment and INH for latent TB; 3) symptomatic TB infection: patients would start with ART and INH treatment for TB infection and co-trimoxazole prophylaxis; 4) symptomatic PCP and TB infections: patients would start with ART and co-trimoxazole treatment and INH treatment; and 5) other opportunistic infections: patients would start with ART and other opportunistic infection therapy such as cryptococcal meningitis and toxoplasma encephalitis. For patient with CD4 counts ≥200 cells per mm$^3$, two possible events were identified: 1) asymptomatic HIV infection: patients would start with ART and 2) symptomatic TB infection: patients would start with ART and INH treatment.

All strategies had potential outcomes, including 1) the development of serious ADRs, 2) other ADRs related to drug therapy, and 3) the absence of ADRs. The benefit of PGx testing strategies was to prevent serious ADRs associated with initial drug regimen by modifying the treatment regimen if the test results were positive, while patients with a negative test result would continue to receive the original drug regimen (Figure 1B).

In each strategy, a Markov model was used to represent the lifetime cost and health outcomes associated with the adoption of ART regimen and opportunistic infection therapy (Figure 1C). Patients who did not acquire any ADRs could remain in this health state or die during the next cycle, as shown in Figure 1C (M1). Patients who developed other ADRs could progress to health state of cure or die in the next cycle (Figure 1C, M2), whereas patients who developed serious ADR could progress to health state of cure or die as a result of those serious ADRs, as shown in Figure 1C (M3). Serious ADRs may be fatal if drugs are not promptly discontinued. Therefore, patients who developed serious ADRs (ie, HSR associated with abacavir, DRESS associated with co-trimoxazole, and SCAR associated with dapsone) would be removed off them. Except for hepatotoxicity associated with isoniazid, the dosage was halved for slow acetylators.

Model Assumptions
The following assumptions were used in this study: 1) no difference in the effectiveness between the first-line and alternative regimens (ie, tenofovir, abacavir and zidovudine-containing regimens) was assumed, 2) patients were assumed to adhere to treatment completely, and 3) since no multiple-PGx testing for people living with HIV was available on the market at the time of this study, its sensitivity and specificity were assumed to be equal to 0.99 referred from the PGxOne$.30$ the panel testing covering more than 60 PGx tests in one panel from major therapeutic areas including gene-drug pairs in this study (ie, HLA-B*$57:01$, HLA-B*$13:01$, and NAT2) and currently available in the market, and 4) The cost of multiple-PGx testing was assumed to be equal to the total cost of four single PGx tests (ie, HLA-B*$57:01$ before prescribing abacavir, HLA-B*$13:01$ before prescribing co-trimoxazole and dapsone, and NAT2 before prescribing isoniazid) in the base-case scenario.
Model Parameters

The input parameters used in the model were classified into four major groups: epidemiological data and transition probabilities, effectiveness of testing, costs data, and utility parameters. The parameter values are presented in Table 1.

Epidemiological Data and Transition Probabilities

The incidence of asymptomatic HIV, symptomatic PCP, or TB patients was retrieved from published studies, which were conducted in Thai people living with HIV before starting ART. The base-case scenario adopted the frequencies of HLA-B*13:01 and NAT2 alleles in Thai HIV-positive people, whereas the frequency of HLA-B*57:01 allele was obtained from white HIV-positive people in Europe and Australia through the PREDICT-1 study. Moreover, The annual mortality rates among HIV asymptomatic, HIV symptomatic, and AIDS patients were estimated using data from two cohort studies of 880 people living with HIV in Thailand. The all-cause mortality rate was derived from the Thai Burden of Disease and Injury Study and was adjusted for age, while mortality rate caused by HSR, DRESS, and SCAR was set at 10%, and hepatotoxicity was 1%.

Figure 1 (A) Decision tree model. (B) Decision tree model (continue). (C) Markov model.

Abbreviations: ABC, abacavir; ADR, adverse drug reaction; ART, Antiretroviral therapy; Asym, asymptomatic; Cotri, Co-trimoxazole; INH, isoniazid; OI, opportunistic infection; NAT2, N-acetyltransferase 2; PCP, pneumocystis pneumonia; Prophy, prophylaxis; Sym, symptomatic; TB, tuberculosis; TDF, tenofovir; Tm, treatment.
| Parameters                                                                 | Distribution | Mean   | Standard Error | Source                          |
|---------------------------------------------------------------------------|--------------|--------|----------------|---------------------------------|
| **Epidemiologic parameter and transitional probabilities**                |              |        |                |                                 |
| **HLA-B*57:01 and abacavir-induced hypersensitivity reaction (HSR)**      |              |        |                |                                 |
| Prevalence of HLA-B*57:01 allele in HIV-infected patients                  | Beta         | 0.067  | 0.01           | Mallal et al 2008              |
| Probability of ABC-induced HSR in patients testing positive for HLA-B*57:01 allele (PPV) | Beta         | 0.604  | 0.07           | Mallal et al 2008              |
| Probability of ABC-induced HSR in patients testing negative for HLA-B*57:01 allele (1-NPV) | Beta         | 0.048  | 0.01           | Mallal et al 2008              |
| Probability of AZT-induced HSR                                           | Fixed        | 0.000  | 0.000          | Dejesus et al 2004             |
| Probability of death due to HSR                                           | Beta         | 0.100  | 0.03           | Plumpton et al 2015            |
| Sensitivity of HLA-B*57:01 screening test                                 | Fixed        | 0.978  |                | Goris et al 2008               |
| Specificity of HLA-B*57:01 screening test                                 | Fixed        | 1.000  |                | Goris et al 2008               |
| **HLA-B*13:01 and co-trimoxazole-induced DRESS**                         |              |        |                |                                 |
| Prevalence of HLA-B*13:01 allele in the Thai population with HIV          | Beta         | 0.179  | 0.04           | Sukasem et al 2020             |
| Probability of co-trimoxazole-induced DRESS in patients testing positive for HLA-B*13:01 allele (PPV) | Beta         | 0.400  | 0.12           | Sukasem et al 2020             |
| Probability of co-trimoxazole-induced DRESS in patients testing negative for HLA-B*13:01 allele (1-NPV) | Beta         | 0.055  | 0.03           | Sukasem et al 2020             |
| Probability of dapsone-induced DRESS                                      | Beta         | 0.040  | 0.01           | Tempark et al 2017             |
| Probability of pentamidine-induced DRESS                                  | Fixed        | 0.000  | 0.000          | Goldie et al, 2002             |
| Probability of death due to DRESS                                         | Beta         | 0.100  | 0.10           | Husain et al 2013              |
| Sensitivity of HLA-B*13:01 screening test                                 | Fixed        | 0.985  |                | Rebecca 2021                  |
| Specificity of HLA-B*13:01 screening test                                 | Fixed        | 0.997  |                | Rebecca 2021                  |
| **HLA-B*13:01 and dapsone-induced SCAR**                                 |              |        |                |                                 |
| Prevalence of HLA-B*13:01 allele in the Thai population                   | Beta         | 0.34   | 0.07           | Tempark et al 2017             |
| Probability of dapsone-induced SCAR in patients testing positive for HLA-B*13:01 allele (PPV) | Beta         | 0.80   | 0.10           | Tempark et al 2017             |
| Probability of dapsone-induced SCAR in patients testing negative for HLA-B*13:01 allele (1-NPV) | Beta         | 0.07   | 0.05           | Tempark et al 2017             |
| Probability of clindamycin plus pentamidine-induced SCAR                 | Beta         | 0.000  |                | Crozier 2011                  |
| Probability of death due to SCAR                                         | Beta         | 0.10   | 0.10           | Husain et al 2013              |
| Sensitivity of HLA-B*13:01 screening test                                 | Fixed        | 0.91   |                | Reslova 2017                   |
| Specificity of HLA-B*13:01 screening test                                 | Fixed        | 0.997  |                | Reslova 2017                   |
| **NAT2 and isoniazid-induced hepatotoxicity**                            |              |        |                |                                 |
| Prevalence of NAT2 allele in the Thai population with TB (n=138)          | Beta         | 0.413  | 0.04           | Wattanapokayakit et al 2016    |

(Continued)
Table 1 (Continued).

| Parameters                                                                 | Distribution | Mean  | Standard Error | Source                                      |
|---------------------------------------------------------------------------|--------------|-------|----------------|---------------------------------------------|
| Probability of INH-induced hepatotoxicity in patients testing positive for NAT2 allele (PPV) | Beta         | 0.667 | 0.06           | Wattanapokayakit et al 2016<sup>13</sup>    |
| Probability of INH-induced hepatotoxicity in patients testing negative for NAT2 allele (1-NPV) | Beta         | 0.185 | 0.04           | Wattanapokayakit et al 2016<sup>13</sup>    |
| Probability of INH low dose-induced hepatotoxicity                        |              | 0.000 |                | Azuma et al 2013<sup>25</sup>               |
| Probability of death due to hepatotoxicity                                | Beta         | 0.008 | 0.01           | Mo et al 2014<sup>21</sup>                  |
| Sensitivity of NAT2 screening test                                        | Fixed        | 0.978 |                | Goris et al 2008<sup>52</sup>               |
| Specificity of NAT2 screening test                                        | Fixed        | 1.000 |                | Goris et al 2008<sup>52</sup>               |
| **Multiple-pharmacogenetic testing**                                      |              |       |                |                                             |
| Sensitivity of multiple-gene screening test by Next Generation Sequencing (NGS) | Fixed        | 1.000 |                | Admera Health PGxOne™ Plus<sup>10</sup>     |
| Specificity of multiple-gene screening test by Next Generation Sequencing (NGS) | Fixed        | 1.000 |                | Admera Health PGxOne™ Plus<sup>10</sup>     |
| Probability of HIV patients with CD4 count ≥200 cells/µL before starting ART | Beta         | 0.553 | 0.553          | Ningsanon et al 2008<sup>11</sup>           |
| Probability of HIV patients with CD4 count <200 cells/µL before starting ART | Beta         | 0.447 | 0.447          | Ningsanon et al 2008<sup>11</sup>           |
| **CD4<200**                                                               |              |       |                |                                             |
| Annual incidences of asymptomatic HIV infected in patients CD4<200 (Baseline CD4 cell count=152) before receiving ART | Beta         | 0.523 | 0.523          | Rojanawiwat et al 2011<sup>12</sup>         |
| Annual incidences of symptomatic PCP with HIV infected in patients CD4<200 before receiving ART (baseline CD4 cell count=152) | Beta         | 0.094 | 0.094          | Rojanawiwat et al 2011<sup>12</sup>         |
| Annual incidences of symptomatic TB with HIV infected in patients CD4<200 before receiving ART (baseline CD4 cell count=152) | Beta         | 0.111 | 0.111          | Rojanawiwat et al 2011<sup>12</sup>         |
| Annual incidences of symptomatic PCP and TB with HIV infected in patients CD4<200 before receiving ART | Beta         | 0.050 | 0.050          | Expert opinion                             |
| **CD4≥200**                                                              |              |       |                |                                             |
| Annual incidences of symptomatic TB with HIV infected in patients CD4≥200 before receiving ART (baseline CD4 cell count=152) | Beta         | 0.010 | 0.010          | Ningsanon et al 2008<sup>11</sup>           |
| **Parametric of survival data**                                           |              |       |                |                                             |
| **Symptomatic (AIDs)**                                                    |              |       |                |                                             |
| Constant in survival analysis for baseline hazard                         | LogNormal    | −4.810| 0.86           | Maleewong et al 2008<sup>17</sup>           |
| Age coefficient in survival analysis for the baseline hazard              | LogNormal    | −0.042| 0.02           | Maleewong et al 2008<sup>17</sup>           |
| CD4 coefficient in survival analysis for baseline hazard                  | LogNormal    | −0.016| 0.00           | Maleewong et al 2008<sup>17</sup>           |
| Ancilliary parameter in Weibull distribution                               | LogNormal    | −0.330| 0.11           | Maleewong et al 2008<sup>17</sup>           |
| Average CD4 of patients (#patients=646)                                   | Normal       | 81.009| 2.670          | Maleewong et al 2008<sup>17</sup>           |

(Continued)
Table 1 (Continued).

| Parameters                                                                 | Distribution | Mean     | Standard Error | Source                        |
|---------------------------------------------------------------------------|--------------|----------|----------------|-------------------------------|
| 1. Cost of testing                                                       |              |          |                |                               |
| Cost of multiple-testing (HLA-B*57:01 and NAT2 and HLA-B*13:01)           | Fixed        | 3000     |                | Estimated                     |
| Cost of HLA-B*57:01 screening test                                        | Fixed        | 1000     |                | MoPH 2021 [44]                |
| Cost of NAT2 screening test                                              | Fixed        | 1000     |                | MoPH 2021 [44]                |
| Cost of HLA-B*13:01 screening test                                        | Fixed        | 1000     |                | MoPH 2021 [44]                |
| 2. Cost of treatment                                                    |              |          |                |                               |
| 2.1 Cost of disease treatment per year                                   |              |          |                |                               |
| Direct medical cost of asymptomatic treatment                           | Gamma        | 14,443   | 14,443         | Leelahavarong et al 2011 [36] |
| Direct non-medical cost of asymptomatic treatment                       | Gamma        | 7202     | 951            | Patient interview             |
| Direct medical cost of symptomatic treatment                            | Gamma        | 29,376   | 29,376         | Leelahavarong et al 2011 [36] |
| Direct non-medical cost of symptomatic treatment                        | Gamma        | 8505     | 2514           | Patient interview             |
| 2.2 Cost of ART regimens per year                                        |              |          |                |                               |
| Annual drug costs of the first-line ART regimens (TDF+FTC+DTG or EFV)   | Gamma        | 10,955   | 2675           | DMSIC, MOPH 2021 [43]         |
| Annual drug costs of the second-line ART regimens (ABC +3TC+DTG or EFV) | Gamma        | 15,579   | 3133           | DMSIC, MOPH 2021 [43]         |
| Annual drug costs of the third-line ART regimens (AZT +3TC+DTG or EFV)  | Gamma        | 10,865   | 3133           | DMSIC, MOPH 2021 [43]         |
| 2.3 Cost of opportunistic infection                                     |              |          |                |                               |
| 2.3.1 Cost of PCP primary prophylaxis per year                           |              |          |                |                               |
| Annual drug costs of the first-line PCP primary prophylaxis with co-trimoxazole | Gamma    | 394      |                | DMSIC, MOPH 2021 [43]         |
| Annual drug costs of the second-line PCP primary prophylaxis with Dapsone | Gamma    | 4380     |                | DMSIC, MOPH 2021 [43]         |
| 2.3.2 Cost of PCP treatment per year                                     |              |          |                |                               |
| Annual drug costs of the first-line PCP treatment with co-trimoxazole in the first year | Gamma    | 9524     |                | DMSIC, MOPH 2021 [43]         |
| Annual drug costs of the first-line PCP treatment with co-trimoxazole in subsequence years | Gamma    | 394      |                | DMSIC, MOPH 2021 [43]         |
| Annual drug costs of the second-line PCP treatment with clindamycin and Primaquine in the first year | Gamma    | 10,004   |                | DMSIC, MOPH 2021 [43]         |
| Annual drug costs of the second-line PCP treatment with clindamycin and Primaquine in subsequence years | Gamma    | 4380     |                | DMSIC, MOPH 2021 [43]         |
| 2.3.3 Cost of TB treatment per year                                      |              |          |                |                               |
| Annual drug costs of the first-line TB treatment with Isoniazid and the first-line ART regimens in the first year | Gamma    | 6082     |                | DMSIC, MOPH 2021 [43]         |
| Annual drug costs of the first-line TB treatment with Isoniazid and the second-line ART regimens in the first year | Gamma    | 8394     |                | DMSIC, MOPH 2021 [43]         |
| Annual drug costs of the first-line TB treatment with Isoniazid and the third-line ART regimens in the first year | Gamma    | 6037     |                | DMSIC, MOPH 2021 [43]         |

(Continued)
Effectiveness of Testing

In the base-case scenario, the probability of drug-induced serious ADRs in patients testing positive for any allele or positive predictive value (PPV) was retrieved from published genetic association studies mainly focusing on Thai population, with the exception of *HLA-B*57:01 study, in which the probability was obtained from PREDICT-1 study. Moreover, the sensitivity and specificity of single-PGx testing were specified by the manufacturer, while those of multiple PGx testing were assumed to be 122% and 33%, respectively.

| Parameters | Distribution | Mean | Standard Error | Source |
|------------|--------------|------|----------------|--------|
| Annual drug costs of the second-line TB treatment with low dose isoniazid and the first-line ART regimens in the first year | Gamma | 6728 | | DMSIC, MOPH 2021 |
| Annual drug costs of the second-line TB treatment with low dose isoniazid and the second-line ART regimens in the first year | Gamma | 9040 | | DMSIC, MOPH 2021 |
| Annual drug costs of the second-line TB treatment with low dose isoniazid and the third-line ART regimens in the first year | Gamma | 6683 | | DMSIC, MOPH 2021 |

3. cost of ADRs treatment

| Parameters | Distribution | Mean | Standard Error | Source |
|------------|--------------|------|----------------|--------|
| Direct medical cost of hypersensitivity reaction treatment per event | Gamma | 27,484 | 10,719 | Patient interview |
| Direct non-medical cost of hypersensitivity reaction treatment per event | Gamma | 1651 | 258 | Patient interview |
| Direct medical cost of DRESS syndrome treatment per event | Gamma | 86,861 | 32,783 | Patient interview |
| Direct non-medical cost of DRESS syndrome treatment per event | Gamma | 780 | 356 | Patient interview |
| Direct medical cost of hepatotoxicity treatment per event | Gamma | 684 | 228 | Patient interview |
| Direct non-medical cost of hepatotoxicity treatment per event | Gamma | 1214 | 277 | Patient interview |
| Direct medical cost of other ADRs per event | Gamma | 1213 | 225 | Patient interview |
| Direct non-medical cost of other ADRs per event | Gamma | 1082 | 136 | Patient interview |

Utility parameters

| Parameters | Distribution | Mean | Standard Error | Source |
|------------|--------------|------|----------------|--------|
| Utility of asymptomatic patients | Beta | 0.860 | 0.01 | Leelahavarong et al 2011 |
| Utility of symptomatic patients | Beta | 0.759 | 0.01 | Leelahavarong et al 2011 |
| Utility of hypersensitivity reaction | Gamma | −0.143 | −0.11 | Plumpton et al 2015 |
| Utility of hepatotoxicity | Gamma | −0.333 | −0.05 | Sadatsafavi et al 2013 |
| Utility of DRESS syndrome | Gamma | −0.143 | | Plumpton et al 2015 |
| Utility of other ADRs | Gamma | −0.012 | −0.00 | Kauf et al 2008 |
| Utility of taken drug regimen (dosing frequency) twice per day vs once daily | Gamma | −0.020 | −0.02 | Kauf et al 2008 |
| Utility of taken drug regimen (dosing frequency) twice per day vs once daily | Gamma | −0.001 | −0.00 | Kauf et al 2008 |

Discounting

| Parameters | Mean | Source |
|------------|------|--------|
| Yearly discount rate for costs | 0.030 | WHO 2003, Thai HTA 2013 |
| Yearly discount rate for outcome | 0.030 | WHO 2003, Thai HTA 2013 |

**Abbreviations:** ABC, abacavir; ADR, adverse drug reaction; ART, antiretroviral therapy; AZT, zidovudine; DRESS, drug rash with eosinophilia and systemic symptoms; DTG, dolutegravir; EFV, efavirenz; FTC, emtricitabine; HSR, hypersensitivity reaction; HLA, human leukocyte antigen; HTA, health technology assessment; INH, isoniazid; NAT2, N-acetyltransferase 2; NPV, negative predictive value; NGS, next generation sequencing; PCP, pneumocystis pneumonia; PGx, pharmacogenetic; PPV, positive predictive value; SCARs, severe cutaneous adverse reactions; TB, tuberculosis; TDF, tenofovir.

**Effectiveness of Testing**

In the base-case scenario, the probability of drug-induced serious ADRs in patients testing positive for any allele or positive predictive value (PPV) was retrieved from published genetic association studies mainly focusing on Thai population, with exception of *HLA-B*57:01 study, in which the probability was obtained from PREDICT-1 study. Moreover, the sensitivity and specificity of single-PGx testing were specified by the manufacturer, while those of multiple PGx testing were assumed to be 122% and 33%, respectively.
be equal to 0.99, referred from PGxOne™, which covered more than 60 PGx tests in one panel from major therapeutic areas, including gene-drug pairs in this study, ie, HLA-B*57:01, HLA-B*13:01 and NAT2.

Cost
All costs were converted and reported in 2022 Thai baht (THB) values using the Thai consumer price index. Cost analysis was performed based on a societal perspective, taking into account both direct medical and non-medical costs. Direct medical costs included costs of ART regimens and opportunistic infection therapy, HIV treatment, ADRs management, single- and multiple-PGx testing. Costs of ART regimens and opportunistic infection therapy were calculated using the unit prices based on public hospital’s prevailing acquisition costs in 2022, announced by the Drug and Medical Supply Information Center (DMSIC), Ministry of Public Health. In addition, costs associated with HIV treatment including laboratory tests, hospitalization, and outpatient department (OPD) follow-up were obtained from a published study. These costs were calculated by multiplying the number of services used by their unit cost. Costs of managing ADRs including abacavir-induced hypersensitivity, co-trimoxazole-induced DRESS, dapsone-induced SCAR, and isoniazid-induced hepatotoxicity were retrieved from Buddhachinaraj Phitsanulok hospital databases containing a total of 465 people living with HIV aged 18 years or older who were hospitalized with serious ADRs in 2015 to 2019. Cost of single-PGx testing was estimated using the reimbursement price of the National Health Security Office (NHSO). Due to lack of data on cost of multiple-PGx testing, we assumed that it was equal to the total cost of three single-PGx tests (ie, HLA-B*57:01, HLA-B*13:01, and NAT2). Nevertheless, the cost’s higher and upper bounds were applied to the uncertainty analysis.

Moreover, direct non-medical costs related to ADRs therapy including transportation to hospitals, food for patients and caregivers, paid caregiver, and informal care (unpaid caregiver) were collected through interviews with 93 patients who had experienced serious ADRs in OPD from the aforementioned hospital.

Utility
Health outcomes were represented as quality-adjusted life-years (QALYs), which are calculated by the multiplying life years (LYs) by their utility score. The utility values (0 = death and 1 = full health) for each health state (ie, hypersensitivity and cure) and a decrease in utility (or disutility) in patients who developed ADRs like hypersensitivity syndrome were obtained from published literatures, in addition to treatment attributes such as dosing frequency (more than once per day) and the number of prescribed pills per day that contributed to the disutility.

Result Presentation
The results were compared to the number needed to screen (NNS) for PGx testing in order to prevent one occurrence of serious ADRs. Total cost, LYs, and QALYs of three alternatives were estimated. The incremental cost-effectiveness ratio (ICER) was calculated by incremental cost divided by incremental QALY of single-PGx or multiple-PGx testing and compared to that of no testing. As recommended by the guidelines for health technology assessment in Thailand, the Thai societal willingness-to-pay threshold (WTP) of 160,000 THB per QALY gained was applied.

Uncertainty Analysis
Parameter Uncertainty
To address the uncertainty of all input parameters and assess their effects on the model, one-way deterministic sensitivity analysis (DSA) and multivariate probabilistic sensitivity analysis (PSA) were performed. DSA was performed by varying each input parameter within its 95% CI, and the Tornado diagram was used to display the range of ICER values. Moreover, PSA using a 1000-time Monte Carlo simulation was conducted to evaluate uncertainty of all parameters simultaneously with appropriate statistical distributions for each parameter, namely the beta-distribution for risks and utility and the gamma distribution for costs parameters. The cost-effectiveness acceptability curve (CEAC) was used to illustrate the probabilities of each alternative being cost-effective relative to a specified WTP threshold.

Scenario Analysis
The scenario analyses were performed by varying the prevalence and PPV of HLA-B*57:01, HLA-B*13:01, and NAT2, as these parameters might have an impact on the ICER values. The prevalence was estimated using the extreme values at the
higher and lower bounds of prevalence in other setting. The prevalence of HLA-B*57:01 was estimated to be 9.5% in Eastern Europe ethnicity \(^47\) and 1.1% in Han Chinese. \(^48\) For HLA-B*13:01, 28% of Papuans and Australian aborigines and 0% of European and African populations \(^49\) were considered. For NAT2, 66% of the UK Caucasian and 10% of Korean population \(^50\) were utilized. Additionally, upper and lower bounds for the PPV were set at 50% of the base case values.

**Threshold Analysis**

Threshold analysis was undertaken to determine the ICER, in which the cost of multiple-PGx testing and the range of its sensitivity and specificity were varied. This analysis sought to determine the threshold at which point the decision would be altered (ie, where the ICER showed that the testing was no longer cost-effective).

**Table 2** Results of Total Lifetime Costs and Health Outcomes from the Base-Case Analysis Using a Societal Perspective

|                                | No-PGx Testing | Single-PGx Testing | Multiple-PGx Testing |
|--------------------------------|----------------|--------------------|----------------------|
| Cost of treatment HIV and co-infection | 1,063,973      | 1,075,229          | 1,078,916            |
| Cost of ADR treatment          | 12,019         | 7891               | 7246                 |
| Cost of testing                | -              | 973                | 3000                 |
| **Total cost (THB)**           | 1,075,992      | 1,084,093          | 1,089,163            |
| Total life year (year)         | 24.87          | 24.92              | 24.96                |
| Total QALYs                    | 20.83          | 20.88              | 20.91                |
| Incremental cost               | 8101           | 13,171             |
| Incremental LYs                | 0.05           | 0.10               |
| Incremental QALYs              | 0.06           | 0.09               |
| **ICER (THB/QALY gain)**       | 146,319        | 152,014            |

**Abbreviations:** ADR, adverse drug reaction; ICER, incremental cost-effectiveness ratio; LY, life year; PGx, pharmacogenetic; PPV, positive predictive value; QALY, quality-adjusted life year; THB, Thai baht.
Results
Base-Case Analysis
Compared with no PGx testing, PGx testing prior to initiating drug therapy could avoid the number of serious ADR cases (ie, abacavir-induced HSR, co-trimoxazole-induced DRESS, dapsone-induced SCAR and isoniazid-induced hepatotoxicity) by approximately 68 cases per year (Figure 2). Furthermore, the number needed to screen (NNS) showed that 40 patients needed to be tested for these PGx tests to prevent one case of serious ADR.

The total lifetime cost, LYs, QALYs, and ICER based on the societal perspective are detailed in Table 2. Compared with no PGx testing, single and multiple-PGx testing were both found to increase LYs and QALYs. Total LYs and QALYs were 24.87 LYs and 20.83 QALYs in the absence of PGx testing, 24.92 LYs and 20.88 QALYs for single-PGx testing, and 24.96 LYs and 20.91 QALYs for multiple-PGx testing. The lifetime costs of single-PGx and multiple-PGx testing were increased by approximately 8101 and 13,171 THB per patient, respectively, whereas QALYs were increased by 0.06 and 0.09, respectively, as compared with no PGx testing. These results indicated that single- and multiple-PGx tests were more slightly higher costs and more advantageous than initiating drug therapy without PGx testing, owing to the cost savings associated with ADR treatment. Consequently, approximately 35% and 40% of the cost of ADR treatment could be avoided by the implementation of single- and multiple-PGx testing, respectively.

The incremental cost-effectiveness ratio was estimated at 146,319 THB/QALY gained for single-PGx testing strategy and 152,014 THB/QALY gained for multiple-PGx testing compared with no PGx testing.
Table 3 Threshold Analysis Showing the Incremental Cost-Effectiveness Ratios (ICER) of Each Scenario, Classified by Cost, Sensitivity and Specificity of Multiple-Pharmacogenetic Testing

| Sensitivity | Specificity= 0.98 | Specificity= 0.99 | Specificity= 1.00 |
|-------------|-------------------|-------------------|-------------------|
|             | 0.95  | 0.96  | 0.97  | 0.98  | 1.00  | 0.95  | 0.96  | 0.97  | 0.98  | 1.00  | 0.95  | 0.96  | 0.97  | 0.98  | 0.99  | 1.00  |
| Cost of panel |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |
| 0           | 134,730 | 138,700 | 142,574 | 146,355 | 150,046 | 153,649 | 98,484 | 102,683 | 106,787 | 110,798 | 114,720 | 118,554 | 65,639 | 69,996 | 74,261 | 78,435 | 82,522 | 86,523 |
| 1000        | 147,149 | 150,950 | 154,660 | 158,280 | 161,813 | 165,263 | 110,424 | 114,469 | 118,423 | 122,287 | 126,064 | 129,758 | 77,135 | 81,352 | 85,478 | 89,517 | 93,472 | 97,343 |
| 2000        | 159,567 | 163,200 | 166,745 | 170,204 | 173,580 | 176,867 | 122,364 | 126,256 | 130,058 | 133,775 | 137,408 | 140,961 | 88,631 | 92,707 | 96,696 | 100,600 | 104,422 | 108,164 |
| 3000        | 171,985 | 175,450 | 178,830 | 182,129 | 185,348 | 188,490 | 134,304 | 138,042 | 141,694 | 145,263 | 148,753 | 152,164 | 100,127 | 104,063 | 107,913 | 111,682 | 115,372 | 118,984 |
| 4000        | 184,404 | 187,700 | 190,916 | 194,053 | 197,115 | 200,104 | 146,244 | 149,828 | 153,330 | 156,752 | 160,097 | 163,367 | 111,623 | 115,418 | 119,131 | 122,765 | 126,322 | 129,804 |
| 5000        | 196,822 | 199,950 | 203,001 | 205,978 | 208,882 | 211,717 | 158,184 | 161,614 | 164,965 | 168,240 | 171,441 | 174,571 | 123,120 | 126,773 | 130,349 | 133,847 | 137,272 | 140,625 |
| 10,000      | 258,914 | 261,200 | 263,428 | 265,600 | 267,719 | 269,785 | 217,883 | 220,545 | 223,144 | 225,682 | 228,163 | 230,587 | 180,601 | 183,551 | 186,437 | 189,260 | 192,022 | 194,726 |
| 20,000      | 383,099 | 383,700 | 384,845 | 385,392 | 385,921 | 385,921 | 337,283 | 338,406 | 339,500 | 340,567 | 341,606 | 342,619 | 295,563 | 297,106 | 298,613 | 300,085 | 301,523 | 302,929 |

Note: The green cell represents that the multiple-pharmacogenetic testing was cost-effective and the red cell represents that the testing was not cost-effective.
Uncertainty Analysis Results

The parameters influencing sensitivity of the ICER for multiple-PGx testing were the cost of ABC-containing regimens, the cost of TDF-containing regimens and probability of death from DRESS, respectively (Figure S1 in Supplementary Materials). Furthermore, when the WTP was 160,000 THB per QALY gained, probability of multiple-PGx testing being cost-effective was 45%, compared to no PGx testing (42%) and single-PGx testing (13%). Moreover, it is important to note that the cost-effectiveness of the multiple-PGx testing increased in correlation with the WTP threshold (Figure 3). The cost-effectiveness plane showed that single- and multiple-PGx testing were more expensive and more effective than no testing (Figure S2 in Supplementary Materials). Additionally, results suggested that there are several uncertainties around the mean of the ICER.

The scenario analyses were performed by varying the value of prevalence and PPV of $HLA^B*57:01$, $HLA^B*13:01$, and $NAT2$. Results from scenario analyses indicated that increases in prevalence and PPV of those tests might result in slightly increased the cost and QALYs of single-PGx testing. However, most scenarios continue to be cost-effective (Table S1 in Supplementary Materials).

Table 3 presents results of threshold analysis upon the ICER of each scenario when the cost of multiple-PGx testing and a range of sensitivity and specificity were varied. Compared to no PGx testing, multiple-PGx testing was shown to be cost-effective under the range of specificity at 0.98–1.00 and sensitivity at 0.95–1.00 as well as the range cost of multiple-PGx testing. For example, if sensitivity and specificity of multiple-PGx testing were both 0.99, multiple-PGx testing would be cost-effective when the cost was less than 3000 THB, but not when the cost exceeded 3000 THB.

Discussion

To the best of our knowledge, this study was the first to investigate the cost-utility of single- and multiple-PGx testing before starting drug therapy in people living with HIV compared to no PGx testing as a current practice. Our results suggested that both single- and multiple-PGx testing could help prevent serious ADRs and reduce the costs of ADR treatment. Moreover, the NNS demonstrated that 40 patients needed to be tested for those PGx to prevent one case of serious ADR. From a societal perspective, both single- and multiple-PGx testing were cost-effective strategies, indicating that they were more expensive and more effective than initiating drug therapy without PGx testing. Moreover, the probability of multiple-PGx testing being cost-effective was 45% compared to no PGx testing (42%) and single-PGx testing (13%) at the Thai willingness to pay threshold of 160,000 THB per QALY.

Currently, although four single PGx testing are available in Thailand and should be performed only once in a lifetime of people living with HIV, there is still low coverage rate of these PGx testing given that these tests have not been included in the UCS health benefit as a result of limited cost-effectiveness information. Hence, the findings from this study could be used to guide policymakers on whether to include either single- or multiple-PGx testing in the UCS health benefit package. These PGx tests may aid in not only identifying the multiple causative genes, but also in developing optimal treatment strategies based on the National Thai HIV treatment guidelines. In addition to this, capacity of PGx services in terms of a referral pathway and genetic counselling services should be considered, while implementing PGx. Alongside this, threshold analysis revealed that multiple-PGx testing was still cost-effective compared to no PGx testing under the range of sensitivity at 0.95–1.00 and specificity at 0.98–1.00 as well as the range cost of multiple-PGx testing. This information can be used to aid in the development of multiple-PGx testing before starting drug therapy in people living with HIV. In parallel with threshold analysis, given that the scenario analysis using a wide range of important parameter values were performed, the finding would be generalizable to other settings. Additionally, the developed method for determining the cost-effectiveness of multiple-PGx testing for preventing drug-induced serious ADRs in people living with HIV may be applied to assess value for money test in other clinical settings.

This study also provided supporting data on host genetic factors in ADRs, which may be helpful in reducing the detrimental effect of drug-induced serious ADRs. Our findings may be considered an extension of traditional approach for treating a disease, which allows clinicians to choose a medication therapy or intervention based on a patient’s genetic profile, a process known as personalized medicine. Furthermore, PGx testing has a significant impact on the rational use
of drugs by reducing the development of side effects and preventing inappropriate treatment adjustment. This may have both therapeutic and economic benefits.

However, it should be noted that some inherent limitations of this study need to be taken into account. First, our analysis did not consider the possibility of different treatment regimens, drug resistance, and poor adherence, which are all conceivable in real practice. Besides this, each serious ADRs and other ADRs related to drug therapy occurred only once during the first year, and we did not consider lifelong ADRs or complications. This may lead to an underestimated value of the one-off testing. Second, due to the scarcity of local data, two input parameters were gathered from other countries. Another caveat is the fact that the prevalence of \( HLA-B*57:01 \) was obtained from the PREDICT-1 trial,\textsuperscript{35} a randomized, multicenter, double-blind trial of \( HLA-B*57:01 \) genotyping abacavir-related HSRs in white Caucasians or Europeans. However, \( HLA-B*57:01 \) testing was included in this study, because abacavir-containing regimen would be a crucial component of an ART backbone regimen as a second-line treatment option for patients who had severe ADRs due to tenofovir or for whom tenofovir was contraindicated. In addition, the Thailand National Guidelines on HIV/AIDS mentioned that \( HLA-B*57:01 \) should be tested before starting abacavir to prevent HSR.\textsuperscript{6} In order to account for this constraint, we performed an uncertainty analysis to assess its effects on the ICER. For the other parameter, dosage adjustments of isoniazid were made in Europe and Japan based on \( NAT2 \) genotype-guided regimen to avoid hepatotoxicity.\textsuperscript{25–27} Taking these limitations into account, however, we conducted one-way and PSA to examine the effect of each parameter on the ICER results. Lastly, we were unable to determine the affordability and ability to implement PGxs testing. To address this challenge, budget impact and feasibility analyses should be executed in a future study.

**Conclusion**

Our findings indicated that both multiple- and single-PGx testing before prescribing HIV therapy could prevent serious ADRs and reduce the costs of ADR treatment. Collectively, given that genetic polymorphisms of several pharmacogenes have been shown to be involved in drug-induced serious ADRs, single- and multiple-PGx testing would be cost-effective options for preventing drug-induced serious ADRs in people living with HIV.

**Ethics Approval**

This study used anonymized and aggregated data related to the cost of managing ADRs conducted by our research team. All participants were required to provide written informed consent before enrolling and the commencement of the study. Ethical approval was granted by the Institutional Review Boards (IRB), Mahidol University (COA.No.MU-DT/PY-IRB 2020/016.1603) through the expedited review procedure. All procedures performed in the study complied with international guidelines for human research protection, such as the Declaration of Helsinki and the Belmont Report.

**Acknowledgments**

This work is a part of a study in Doctor of Philosophy program in Social, Economic and Administrative Pharmacy (SEAP), Faculty of Pharmacy, Mahidol University, Bangkok. Besides, this study was supported by grants from the International Research Network-The Thailand Research Fund (IRN60W003) and Health Systems Research Institute (HSRI61-080), Thailand. However, the funders had no role in the design, conduct of the study; collection, management, analysis and interpretation of data, and preparation of the manuscript. We would like to thank Miss. Waranya Rattanavipapong for her valuable advice. Our gratitude is also extended to all patients who participated in this study.

**Disclosure**

The authors declare no conflicts of interest in relation to this work.

**References**

1. The Thai Working Group on Burden of Disease and Injuries. Burden of disease and injuries in Thailand; 2002.
2. Country factsheets Thailand; 2019. Available from: https://www.unaids.org/en/regionscountries/countries/Thailand. Accessed April 6, 2021.
3. HIV Epidemic. Available from: https://hivhub.ddc.moph.go.th/epidemic.php. Accessed April 6, 2021.
26. Kinzig-Schippers M, Tomalik-Scharte D, Jetter A, et al. Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?

22. World Health Organization. Guidelines on Co-Trimoxazole Prophylaxis for HIV-Related Infections Among Children, Adolescents and Adults: Recommendations for a Public Health Approach. World Health Organization; 2006.

23. World Health Organization. Guidelines for treatment of tuberculosis, 4th ed. Available from: http://www.who.int/tb/publications/2010/9789241547833/en/. Accessed July 1, 2021.

24. Department of Disease Control, Ministry of Public Health. Thailand National Guidelines on TB/HIV 2017. Thailand: Department of Disease Control, Ministry of Public Health; 2020.

25. Azuma J, Ohno M, Kubota R, et al. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. *Eur J Clin Pharmacol*. 2013;69(5):1091–1101. doi:10.1007/s00228-012-1429-9

26. Kinzig-Schippers M, Tomalik-Scharte D, Jetter A, et al. Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? *Antimicrob Agents Chemother*. 2005;49(5):1733–1738. doi:10.1128/aac.49.5.1733-1738.2005

27. Kubota R, Ohno M, Hasunuma T, Iijima H, Azuma J. Dose-escalation study of isoniazid in healthy volunteers with the rapid acetylator genotype of arylamine N-acetyltransferase 2. *Eur J Clin Pharmacol*. 2007;63(10):927–933. doi:10.1007/s00228-007-0333-1

28. Tan-Torres Edejer T, Baltussen R, Adam T, et al. Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis. World Health Organization; 2003.

29. Chaikledkaew U, Teerawattananon Y. Personalized therapy in HIV-1 infected adults and adolescents 2014. Thailand. *AIDS Res Ther*. 2015;12:12. doi:10.1186/s12981-015-0053-z

30. Adolescents PoAGfAa. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Available from: https://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed April 6, 2021.

31. Department of Disease Control, Ministry of Public Health. Thailand National Guidelines on HIV/AIDS Diagnosis, Treatment and Prevention 2020/2021. Thailand: Department of Disease Control, Ministry of Public Health; 2020.

32. Rodríguez-Nóvoa S, Barreiro P, Jiménez-Nácher I, Soriano V. Overview of the pharmacogenetics of HIV therapy. *Pharmacogenomics J*. 2006;6(4):234–245. doi:10.1038/sj.tpj.6500374

33. Wattanapokayakit S, Mushiroda T, Yanai H, et al. NAT2 slow acetylator associated with anti-tuberculosis drug-induced liver injury in Thaipatients. *Int J Tuberc Lung Dis*. 2011;15(1):68–76. doi:10.1016/j.ijtld.2010.09.011

34. Wang C-W, Tassaneeyakul W, Chen C-B, et al. Whole genome sequencing identifies genetic variants associated with co-trimoxazole hypersensitivity in Asians. *J Allergy Clin Immunol*. 2021;147(4):1402–1412. doi:10.1016/j.jaci.2020.08.003

35. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to Abacavir. *Clin Pharmacol Ther*. 2018;103(5):1078–1089. doi:10.1002/cpt.1915

36. Leelahavarong P, Teerawattananon Y, Werayingyong P, et al. Is a HIV vaccine a viable option and at what price? An economic evaluation of adding HIV vaccination into existing prevention programs in Thailand. *BMCPublic Health*. 2011;11:534. doi:10.1186/1471-2458-11-534
37. Maleewong U, Kulsumboon V, Teerawattananon Y. The cost-effectiveness analysis of initiating HIV/AIDS treatment with efavirenz-based regimens compared with nevirapine-based regimens in Thailand. J Med Assoc Thai. 2008;91(Suppl 2):S126–38.
38. Leelukkanaveera Y. An Economic Evaluation of Routine Offer HIV Counseling and Testing of Out Patients at Community Hospitals in Thailand. Chulalongkorn University; 2009.
39. Plumpton CO, Yip VL, Alfirevic A, Marson AG, Pirmohamed M, Hughes DA. Cost-effectiveness of screening for HLA-A*31:01 prior to initiation of carbamazepine in epilepsy. Epilepsia. 2015;56(4):556–563. doi:10.1111/epi.12937
40. Husain Z, Reddy BY, Schwartz RA. DRESS: part I. Clinical perspectives. J Am Acad Dermatol. 2013;68(5):693.e1-e14; quiz 706–708. doi:10.1016/j.jaad.2013.01.033
41. Mo P, Zha Q, Teter C, et al. Prevalence, drug-induced hepatotoxicity, and mortality among patients multi-infected with HIV, tuberculosis, and hepatitis virus. Int J Infect Dis. 2014;28:95–100. doi:10.1016/j.ijid.2014.06.020
42. Ministry of Commerce. Report for consumer price index of Thailand. Available from: http://www.indexpr.moc.go.th/price_present/TableIndexG_region.asp?table_name=cpig_index_country&province_code=5&type_code=g&check_f=i&year_base=2562&nyear=2552. Accessed June 1, 2021.
43. Ministry of Public Health. Drug And Medical Supply Information Center. Available from: http://dmsic.moph.go.th/index/drugssearch/1. Accessed September 1, 2021.
44. Department of Medical Sciences MoPH. Service fee for analysis and service. Available from: https://www3.dmsc.moph.go.th/. Accessed September 1, 2021.
45. Kauf TL, Roskell N, Shearer A, et al. A predictive model of health state utilities for HIV patients in the modern era of highly active antiretroviral therapy. Value Health. 2008;11(7):1144–1153. doi:10.1111/j.1524-4733.2008.00326.x
46. Sadatsafavi M, Marra C, Marra F, Moran O, FitzGerald JM, Lynd L. A quantitative benefit-risk analysis of isoniazid for treatment of latent tuberculosis infection using incremental benefit framework. Value Health. 2013;16(1):66–75. doi:10.1016/j.jval.2012.09.006
47. Wolf E, Blankenburg M, Bogner JR, et al. Cost impact of prospective HLA-B*5701-screening prior to Abacavir/lamivudine fixed dose combination use in Germany. Eur J Med Res. 2010;15(4):145–151. doi:10.1186/2047-783X-15-4-145
48. Kapoor R, Martinez-Vega R, Dong D, et al. Reducing hypersensitivity reactions with HLA-B*5701 genotyping before Abacavir prescription: clinically useful but is it cost-effective in Singapore? Pharmacogenet Genomics. 2015;25(2):60–72. doi:10.1097/PCG.0000000000000107
49. Satapornpong P, Finda P, Jantararoungtong T, et al. Genetic diversity of HLA class I and Class II alleles in Thai populations: contribution to genotype-guided therapeutics. Front Pharmacol. 2020;11:78. doi:10.3389/fphar.2020.00078
50. Retno WS, Kinasih P, Intan R, Syukrini B, Rika Y. High frequency of NAT2 slow acetylator alleles in the Malay population of Indonesia: an awareness to the anti-tuberculosis drug induced liver injury and cancer. Med J Indones. 2017;26(1). doi:10.13181/mji.v26i1.1563
51. DeJesus E, Herrera G, Teofilo E, et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis. 2004;39(7):1038–1046. doi:10.1086/424009
52. Goris A, Walton A, Ban M, Dubois B, Compton S, Sawyer S. A Taqman assay for high-throughput genotyping of the multiple sclerosis-associated HLA-DRB1*1501 allele. Tissue Antigens. 2008;72(4):401–403. doi:10.1111/j.1399-0039.2008.01101.x
53. Goldie SJ, Kaplan JE, Losina E, et al. Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines. Arch Intern Med. 2002;162(8):921–928. doi:10.1001/archinte.162.8.921
54. Rebecca E. Sanger sequencing: past successes and current applications. Available from: http://www.1000genomes.org/studies/1000genomes-1000genomes-1000genomes, 2017.
55. Reslova N, Michna V, Kasny M, Mikel P, Kralik P. xMAP technology: applications in detection of pathogens. Front Microbiol. 2017;8:555. doi:10.3389/fmicb.2017.00555

ClinicoEconomics and Outcomes Research

Publish your work in this journal

ClinicoEconomics and Outcomes Research is an international, peer-reviewed open-access journal focusing on Health Technology Assessment, Pharmacoeconomics and Outcomes Research in the areas of diagnosis, medical devices, and clinical, surgical and pharmacological intervention. The economic impact of health policy and health systems organization also constitute important areas of coverage. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/clinicoeconomics-and-outcomes-research-journal

ClinicoEconomics and Outcomes Research 2022:14

Dovepress

463

Dovepress